Jiuzhou Pharmaceutical(SH:603456) Zheng Quan Shi Bao Wang·2025-11-12 00:28Core Viewpoint - The transfer of shares from Hua Xuande to his daughters marks a significant change in the ownership structure of Zhongbei Group and its indirect control over Jiuzhou Pharmaceutical, with the daughters becoming the new actual controllers of the company [1][2]. Group 1: Share Transfer Details - Hua Xuande plans to transfer 42.50% of his shares in Zhongbei Group and 10% in Taizhou Gede to his daughters, Hua Lirong and Hua Xiaohui, with payments of 41.33 million yuan and 20.48 million yuan respectively [1]. - The transferred shares correspond to an estimated market value of approximately 2.476 billion yuan in Jiuzhou Pharmaceutical [1]. Group 2: Impact on Company Control - Following the share transfer, Hua Xuande will no longer hold any shares in Zhongbei Group or Taizhou Gede, thus ceasing to have indirect control over Jiuzhou Pharmaceutical [2]. - The new actual controllers of Jiuzhou Pharmaceutical will be Hua Lirong, who is currently the chairman, and Hua Xiaohui, who has resigned from her director position [2]. Group 3: Hua Xuande's Contributions - Hua Xuande has significantly contributed to the development of Zhongbei Group and Jiuzhou Pharmaceutical, transforming the company from a struggling entity into a prominent player in the industry [2]. - Under his leadership, Jiuzhou Pharmaceutical was established in 1998 and went public in 2014, marking a pivotal moment in the company's history [2]. Group 4: Recent Developments - Hua Xuande remains the chairman of Zhongbei Group and holds director positions in other companies, despite stepping back from direct involvement in Jiuzhou Pharmaceutical [3]. - Recent news regarding the criminal detention of a related figure in the industry has brought Hua Xuande back into the spotlight, highlighting his connections within the sector [4].